Hikma Narrows Annual Profit Outlook Toward Higher End
Hikma narrowed its annual profit forecast range closer to the higher end as branded-medicines demand in the Middle East and North Africa offset pressure in its injectables division.
Britain's Hikma Pharmaceuticals LSE:HIK on Thursday narrowed its annual profit forecast range closer to the higher end as strong demand in its branded business across in the Middle East and North Africa offset pressure in the injectables division.